Hepatitis C: a critical analysis of therapeutic response predictors

Focaccia, R; Siciliano, R. F; Santos, E. D. B; Boccardo, E; Conceição, O. J. G; Barbosa, U. O; Galante, V. C

Focaccia, R; Siciliano, R. F; Santos, E. D. B; Boccardo, E; Conceição, O. J. G; Barbosa, U. O; Galante, V. C.

Focaccia, R; Emílio Ribas Infectious Diseases Institute. São Paulo. BR
Siciliano, R. F; Emílio Ribas Infectious Diseases Institute. São Paulo. BR
Santos, E. D. B; Emílio Ribas Infectious Diseases Institute. São Paulo. BR
Boccardo, E; Emílio Ribas Infectious Diseases Institute. São Paulo. BR
Conceição, O. J. G; Emílio Ribas Infectious Diseases Institute. São Paulo. BR
Barbosa, U. O; Emílio Ribas Infectious Diseases Institute. São Paulo. BR
Galante, V. C; Emílio Ribas Infectious Diseases Institute. São Paulo. BR

Braz. j. infect. dis ; 6(2): 74-81, Apr. 2002.

Article in English | LILACS, SES-SP | ID: lil-332307

RESUMO

RESUMO

Treatment of chronic hepatitis C is still unspecific. However, there is great expectancy concerning the new pegylated interferons. As there has been much controversy about the best parameters to determine whether treatment is effective, we analyzed several criteria currently used for evaluation, including serum alanine aminotransferase (ALT) normalization, viral load reduction and improvement of hepatic histology.

Subject(s)

Humans; Drug Evaluation/methods; Drug Evaluation/standards; Hepatitis C, Chronic/blood; Hepatitis C, Chronic/drug therapy; Antiviral Agents; Interferons; Hepacivirus; Viral Load; Alanine Transaminase; Liver/pathology; Liver/virology; Hepatitis C, Chronic/virology

Fulltext

XML

Search on Google

Full text: Available Index: LILACS (Americas) Main subject: Hepatitis C, Chronic / Drug Evaluation Type of study: Prognostic study / Risk factors Limits: Humans Language: English Journal: Braz. j. infect. dis Year: 2002 Type: Article Institution/Affiliation country: Emílio Ribas Infectious Diseases Institute/BR

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google